Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Artificial Blood Vessels Market size was over USD 2.1 billion in 2024 and is estimated to reach USD 4.6 billion by the end of 2037, expanding at a CAGR of 9% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of artificial blood vessels is evaluated at USD 2.3 billion.
The increasing prevalence of cardiovascular disease (CVD) and diabetes-related complications is the primary driver behind the growth of the artificial blood vessels market. In this regard, the WHO reported that the number of ischemic heart disorders (IHD) around the world surpassed 500.3 million in 2024. Further, in 2025, the European Centre for Disease Prevention and Control (ECDC) calculated the total number of CVD-afflicted people alone in Germany to be 2.5 million, which showcased a 14.2% growth from 2020. This enlarging demography presents a sustainable demand worldwide for associated interventional components, including vascular grafts, pushing both MedTech pioneers and healthcare authorities to invest in this sector.
Excessive financial exhaustion has always been a root cause of this disparity, which is inflated by cost volatilities in the raw material supply chains, production, and regulatory compliance. Thus, the magnifying economic burden on patients is currently a significant issue to resolve for leaders in the artificial blood vessels market. This can be displayed through the upward trajectory of payer's pricing in different stages of conducting business operations. For instance, in 2023, the producer price index (PPI) for surgical appliances rose by 6.9% year-over-year (YoY). This was caused by the disruptions in sourcing medical-grade polymer during the pandemic, reflecting an overall 12.3% increase in producer price. Subsequently, the consumer price index (CPI) for surgical implants grew by 4.4%.
Artificial Blood Vessels Sector: Growth Drivers and Challenges
Growth Drivers
- Clinical and operational advantages: Several medical trials have evaluated and established remarkable benefits of utilizing the commodities from the artificial blood vessels market. Testifying this, in 2022, the Agency for Healthcare Research and Quality (AHRQ) published a study on this aspect, demonstrating a 22.4% reduction in hospital admissions for CABG due to allowing interventions with these surgical components at an early stage. It also highlighted the potential of these operations to save more than USD 850.2 million over 2 years. Such evidence, coupled with enhanced outcomes, constructed a strong foundation for this merchandise and currently inspiring more participants and patients to invest in this sector.
- Innovational and regulatory support: The integration of next-generation technologies in related surgeries has stimulated the adoption and utilization rates in the artificial blood vessels market. Particularly, the recent penetration of AI and 3D printing in producing various crucial surgical instruments, is helping dedicated pipelines provide better precision and user convenience. In this cohort, the support from stringent regulatory frameworks is also fastening this progress. For instance, Humacyte gained accelerated 510(k) clearance from the FDA for its 3D-printed vessels in 2024. This milestone was backed by the ability of the company's bioengineered grafts to present a 40.1% reduction in rejection rates.
Historical Patient Growth (2010-2020) and Its Impact on Market Expansion
The rapid increase in the number of citizens with CVD, diabetes, and chronic kidney disease (CKD) during the timeline from 2010 to 2020 underscored a transformative phase in the artificial blood vessels market. In addition, the amplification in the highly prone patient population due to aging and the pandemic drew a significant contribution to this demographic transition. For instance, throughout this tenure, the frequent occurrence of coronary artery disease (CAD), peripheral artery disease (PAD), and end-stage renal disease (ESRD) boosted the patient pool by 12.3% annual growth in key landscapes, such as the U.S., Germany, Japan, and China. Moreover, this expansion shaped the current dynamics of scalability and personalization.
Historical Patient Growth (2010-2020) in Key Markets
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
CAGR (2010-2020) |
Primary Driver |
|
U.S. |
0.9 |
1.7 |
6.8% |
Medicare coverage for CABG & PAD grafts |
|
Germany |
0.3 |
0.6 |
7.9% |
Early bio-graft adoption |
|
France |
0.2 |
0.5 |
8.3% |
Rising ESRD cases |
|
Spain |
0.2 |
0.3 |
8.5% |
Aging population |
|
Australia |
0.09 |
0.2 |
8.6% |
Minimally invasive surgery trends |
|
Japan |
0.4 |
0.8 |
8.9% |
High dialysis access demand |
|
India |
0.2 |
0.4 |
9.8% |
Untapped CAD/PAD patient pool |
|
China |
0.5 |
1.06 |
9.7% |
Healthcare infrastructure growth |
Feasible Expansion Models Shaping the Future of Artificial Blood Vessels Market
The pathways followed by key players are drafting a reliable structure of commercial roadmap for the artificial blood vessels market. Both new entrants and existing competitors can benefit from their strategic moves, as they lead to significant success in region-specific operations. For instance, the associated suppliers in India found the method to be underlying alliance formation with local medical service providers, which boosted revenue by 12.4% over the previous tenure between 2022 and 2024. Similarly, the alignment with domestic reimbursement policies and government subsidies showcased their potential to bolster bio-graft adoption by 25.1% in Germany by 2026. Furthermore, localized production and product innovation are also fueling this cohort of global expansion in this field.
Feasibility Models for Market Expansion (2025-2030)
|
Region |
Strategy |
Revenue Impact |
|
(USD Billion) |
|
|
|
India |
Hospital partnerships |
+12.4% (2022-2024) |
|
Germany |
Full bio-graft reimbursement |
+25.1% adoption by 2026 |
|
U.S. |
ASC-focused distribution |
+22% procedural volume |
Challenge
- Economic disparity and competition with alternatives: The limitations in comprehensive pricing are a major hurdle in maintaining competency for leaders in the artificial blood vessels market. Thus, the strengthening presence and emergence of other cost-effective solutions are making it hard for available products in this sector to survive amid the competition with alternatives. For instance, the lower up-front cost of stent grafts helped this product capture over 45.2% of the Europe landscape. However, companies are investing in extensive R&D to develop affordable options with long-term benefits. In this regard, Humacyte allocated USD 50.3 million in NIH-backed clinical trials to establish the competitive credibility of its bioengineered vessels in this scenario.
Artificial Blood Vessels Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9% |
|
Base Year Market Size (2024) |
USD 2.1 billion |
|
Forecast Year Market Size (2037) |
USD 4.6 billion |
|
Regional Scope |
|
Artificial Blood Vessels Segmentation
Material Type (Synthetic, Bioengineered, Hybrid)
In terms of material types, the bioengineered segment is predicted to dominate the artificial blood vessels market with a share of 42.2% by the end of 2037. It offers higher possibilities of attaining affordability in this sector, making this segment the most attractive option for both manufacturers and patients. This leadership is also supported by continuous R&D investments from dedicated organizations. For instance, in 2023, net public and private capital allocation for R&D on bioengineered vessels crossed USD 2.2 million, backed by DARPA and Horizon Europe funding for 3D-printed vascular networks. Furthermore, the sustainable characteristics of this material are accelerating the process of regulatory approvals. For instance, in 2024, 3 acellular vessel products received fast-tracked clearance from the FDA.
Application (Coronary Artery Bypass Grafts (CABG), Peripheral Vascular Repair, Dialysis Access)
Based on applications, the coronary artery bypass grafts (CABG) segment of artificial blood vessels market is anticipated to garner the highest revenue share of 38.4% throughout the analyzed timeframe. The amplifying mortality from CVD is pushing authorities and service providers to fetch long-lasting interventional solutions, such as coronary artery bypass surgeries, fueling demand in this sector. As evidence, in 2024, the WHO revealed that the number of deaths from this disease around the globe was 18.7 million every year. Additionally, the reinforcement strategies, applied by governing bodies, tend to incorporate artificial components, including vessels, ensuring consistent adoption and a stable cash inflow from this segment.
Our in-depth analysis of the global artificial blood vessels market includes the following segments:
|
Material Type |
|
|
Application |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Artificial Blood Vessels Industry - Regional Synopsis
North America Market Analysis
North America is projected to capture the largest share of 40.2% in the global artificial blood vessels market over the assessed period. This proprietorship is highly fueled by the established healthcare system, reimbursement structure, and ongoing tech-based innovations. Moreover, the funding support from both the Federal government and academic institutions is drafting a strong base for extensive R&D and pipeline expansion in this sector. The enlarging burden of the obese and diabetic population is also fueling demand in this sector. For instance, in 2024, the yearly count of patients with Peripheral Artery Disease and diabetes, requiring vascular grafts, was 12.3 million, as per the Centers for Disease Control and Prevention (CDC).
The U.S. artificial blood vessels market is augmenting dominance in the regional landscape with an 85.2% revenue share. This can be testified by the notable annual CVD prevalence among 18.7 million citizens. In addition, in 2024, the expenditure by Medicare on products available in this sector reached USD 800.5 million, underscoring a rise of 15.2% from 2020. The rapid penetration and adoption of ambulatory surgical centers (ASCs) across the country are also outperforming hospitals in contribution to the utilization of grafts, with a 22.1% higher graft-related surgical operations performed.
Canada is also standing at the forefront of the regional artificial blood vessels market with its remarkable improvement in healthcare access for elder citizens. Considering the importance of cultivating sufficient resources to avail adequate facilities for afflicted residents on time. In this regard, the government of Ontario raised its clinical investments by 18.4% from 2021 to 2024. Moreover, the country's significance can also be testified by the number of performed graft procedures each year, which crossed 200,010, according to the Canadian Institute for Health Information. Further, the nationwide subsidized deployment of 3D-printed vessel adoption is also propelling growth in this sector.
APAC Market Statistics
The Asia Pacific artificial blood vessels market is poised to witness the highest pace of growth by 2037, exhibiting a 9.3% CAGR. Having the largest population of CVD patients in the world, accounting for 60.2%, the implementation of government healthcare initiatives is becoming more frequent than ever, according to the WHO. In addition, the diverse propagation pathways of both developed and emerging economies, including China, Japan, and India, are broadening the scope of investments in this sector. Furthermore, the trend of healthcare modernization and infrastructural development is also increasing demand for surgical-robot-compatible solutions, marking a progressive business atmosphere.
China is propagating the artificial blood vessels market with its excellence in surgical instrument production and a widening patient pool. According to the National Medical Products Administration (NMPA), the number of residents afflicted with related ailments crossed 1.6 million in 2023. Simultaneously, in 2024, the same organization provided clearance to eight new grafts, displaying the growing acceptance of advancements. Furthermore, the 15.4% increase in expenditure by governing bodies on vascular care over five years is helping mitigate disparities among rural and urban healthcare systems.
South Korea is emerging as a hub of innovation for the regional artificial blood vessels market, backed by deepening nationwide penetration of robotic-assisted grafts. The government and private initiatives to indulge cutting-edge solutions into the existing pipeline through extensive R&D are propelling this pace of progress in the country. For instance, in 2024, a USD 500.3 million fund was allocated by the governing bodies of this nation to advance AI-driven vascular technologies. Moreover, the extension of pioneering research to shape the future of vascular care is solidifying the country's augmentation in tech-based discoveries.
Companies Dominating the Artificial Blood Vessels Landscape
- B. Braun Melsungen AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Medtronic plc
- Cook Medical Incorporated
- Becton, Dickinson and Company (BD)
- Humacyte Inc.
- Jotec GmbH
- LeMaitre Vascular Inc.
- Techshot Inc.
- W. L. Gore & Associates
- Boston Scientific Corporation
- Abbott Laboratories
- MicroPort Scientific Corporation
- Samsung Healthcare
- United Surgical Industries
- Malaysia Healthcare Innovations
- Elekta AB
- Getinge AB
- Straub Medical AG
The current dynamics of the artificial blood vessels market are stimulated by fierce competency among key players, associated with ongoing technological advances and global expansion. Their strategic commercialization ensures maximum financial output from this merchandise. For instance, Humacyte and Medtronic concentrated their focus on producing bioengineered acellular vessels to consolidate the safety profiles and effectiveness of their pipelines. On the other hand, Terumo and BD magnify their efforts to develop and commercialize synthetic grafts to cope with the growing demand from minimally invasive applications.
Top 20 of these innovators are:
Recent Developments
- In March 2024, LeMaitre Vascular expanded the commercial rollout of its ArtAssist device, enhancing artificial blood vessel integration for improved peripheral arterial disease (PAD) outcomes. The launch drove a 9.4% revenue increase in the 1st quarter of 2024, with projections to capture 15.1% of the PAD treatment market.
- In February 2024, W. L. Gore & Associates launched the GORE ACUSEAL Vascular Graft, featuring proprietary sealing technology to minimize bleeding complications in hemodialysis patients. The product drove a 7.2% revenue increase in Gore’s medical division, with over 5,004 units sold globally in its first quarter.
- Report ID: 3743
- Published Date: Jun 10, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Artificial Blood Vessels Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
